Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial
第一作者单位:[1]Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Dept Hematol,Affiliated Hosp 1, Nanjing 210029, Peoples R China
推荐引用方式(GB/T 7714):
Xu Wei,Liang Jin-Hua,Wang Li,et al.Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial[J].BLOOD.2022,140:9484-9485.doi:10.1182/blood-2022-157014.
APA:
Xu, Wei,Liang, Jin-Hua,Wang, Li,Wang, Xiao-Dong,Cui, Guohui...&Li, Jian-Yong.(2022).Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial.BLOOD,140,
MLA:
Xu, Wei,et al."Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial".BLOOD 140.(2022):9484-9485